Study how the microbiome may affect breast implant infections
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study looks at whether changes in the body’s “microbiome” (the normal germs in and on the body) are linked to infections after breast surgery with implants. It may help doctors better predict and prevent implant infections in people undergoing mastectomy with immediate implant placement.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have breast cancer confirmed by biopsy OR a genetic risk for breast cancer
- You are planning a mastectomy with immediate tissue expander or implant placement
- You completed chemotherapy or radiation at least 4 weeks ago
- You can read and sign the informed consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how bacteria in the gut and tumor affect breast cancer in women having surgery. The goal is to learn more about the cancer to improve treatment in the future.
This study gives a probiotic to see whether it safely changes the gut’s bacteria and fungi (your “microbiome”) in people with breast cancer. The researchers want to learn if this shift in gut microbes might support breast cancer treatment or health during care.
This trial tests whether placing antibiotic beads near the surgical site during breast reconstruction can help prevent infections. It is for women having a mastectomy followed by immediate breast reconstruction with a tissue expander.
This trial looks at whether having breast implants changes what happens during routine breast cancer screening with mammograms. It may help improve how screening is done and understood for people with implants.
This study looks at how abemaciclib (Verzenio) affects the bacteria in your gut (the microbiome). If you have a certain type of breast cancer and are starting this treatment, researchers want to understand why it works the way it does.
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.